CTLA4 and neoplasm: An issue with immunotherapy treatments combining targeted monoclonal antibodies such as those targeting tumor-associated antigens such as trastuzumab (Her-2) and immune checkpoints such as pembrolizumab (PD1), nivolumab (PD1) and ipilimumab (CTLA4) is that their combination can add toxicity and cost of treatment.